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From 1 January 2005 every UK doctor will need a licence to practise. Most doctors will be able to
secure revalidation of their licence by annual appraisal and by showing that they are compliant with
local clinical governance requirements and free of any serious unresolved concerns about their
fitness to practise
In May 2001, the General Medical Council confirmed
that all doctors would have to show regularly that they
remained up to date and fit to practise in their chosen
field. This process was termed revalidation, and its
introduction was said to be a landmark in the history of
self regulation of the medical profession.
The decision was made against a background of
high profile cases of medical malpractice and
coincided with the first term of a new government
which had a mandate to modernise the health service.
Indeed the years since the 1997 election have been
characterised by a range of policy developments affect-
ing the regulation of doctors in the NHS (see table A
on bmj.com). These have included the contractual
need to participate in annual appraisal and the profes-
sional obligation to undergo revalidation.
Recent guidance indicates that revalidation may be
achieved through participating in annual appraisal.1
What then is the purpose of revalidation?
The emerging role of revalidation
In late 2001 I did research to analyse the development of
policy between May 1997 (the election of the new
government) and July 2001 (the publication of the
report of the Bristol Inquiry) with particular respect to
the revalidation of general practitioners. The overall aim
of the study was to examine the emerging role of revali-
dation in relation to other changes in professional and
contractual regulation.2
The three key stakeholders (with political power)
directly involved in negotiating the emergent policy
were the profession, the government, and the General
Medical Council (the profession’s regulator). The main
focus of my research was on their contribution to policy
development, and I used three principal sources of data:
x Stakeholders’ key policy documents—those which
affected or potentially affected the professional or con-
tractual regulation of general practitioners
x A sample of the responses to the Royal College
of General Practitioners’ consultation exercise on
revalidation.
x In-depth interviews with 18 key opinion leaders and
policy makers (box).
Beyond the immediate antecedent of the Bristol
case, I concluded that revalidation stemmed from vari-
ous causes. Firstly, failure—failure of the systems, which
were meant to assure the public that the care they
received was satisfactory; and failure of the prevailing
medical culture to change with the times. The govern-
ment largely attributed these failings to their predeces-
sor’s internal market.3 However, by 1998 they were also
referring directly to the series of well publicised lapses,
which they said had dented public confidence.4 These
were then developed into the more general theme of
unacceptable variations in practice,4 and by 1999 the
government was being specific in its concern about
poorly performing doctors.5
A second antecedent, that revalidation was part of a
progressive development of the profession by the pro-
fession, was a view particularly emanating from the
regulator and the profession. Conversely a number of
the opinion leaders saw revalidation as part of a
complex political readjustment between the main
stakeholders.
In terms of the purpose of revalidation there were
three over-riding themes: securing public trust,
promoting continuing professional development, and
detecting poor performance, with recognition that the
Summary points
Revalidation is a watershed in medical self
regulation in the United Kingdom
Stakeholders agreed on the policy in principle
but disagreed on its operation
Confusion and unease exist about whether
revalidation is intended to detect poor performers
and its overt link with appraisal
Ultimately separating revalidation from appraisal
may be sensible; doctors can do this by following
the “independent route” rather than the
“appraisal route” to revalidation
Table A summarising the documents affecting relevant policy
developments is on bmj.com
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purpose might be multifaceted. The government iden-
tified rebuilding public confidence in the NHS as one
of its main tasks.6 Events, they said, had strained the
vital bond of trust between doctors and patients.7
All identified the tension inherent in a single proc-
ess, which was designed both to improve the many and
to detect the few poor performers. Each group of
stakeholders, however, identified both as purposes of
revalidation. On balance, the detection of poor
performance seemed to be uppermost in the minds of
the government and the responders to the consulta-
tion exercise. There was some support for the idea that
revalidation would act as a screening device for poor
performers, though doubts about how effective it
might be and whether it should be seen in that way.
The government set out to describe how the raft of
policies from government and regulator would
together assure the quality of medical practice.6 The
regulator also defined the relation between revalida-
tion and various other processes, including appraisal.8
Among the responses to the consultation exercise
there were few references to other processes, except to
suggest that revalidation was a duplication. At that time
many of the opinion leaders were unclear about the
relation between the new structures and processes—for
example, the role of the National Clinical Assessment
Authority in relation to the General Medical Council.
“It’s just alphabet soup as far as the average patient
goes,” said C Rayner, chair of the Patients Association,
in a personal communication.
A consensus on revalidation?
At one level consensus was reached on the policy
throughout, and revalidation was referenced appropri-
ately in policy documents. And the consultation
exercise also showed that most general practitioner
responders (1569 out of 1946; 81%) were “broadly in
support.”2 Many adverse comments were, however,
given even in the supportive responses, including
objections in principle; anxiety about the process, its
funding and its effect on general practice; and
apprehension about how general practitioners could
be expected to meet the requirements of revalidation
given the constraints of the health service.
None of the opinion leaders voiced any substantial
objection to revalidation. Concerns were expressed,
however, about the process and whether it would
deliver the desired outcomes. In particular, would
revalidation redress unacceptable variation in practice
or prevent high profile medical failure?
The future regulation of doctors
Stakeholders also expressed disquiet about the
implications for the regulation of doctors in the future.
Among the comments to the consultation exercise, in
which respondents forecasted future consequences,
two themes were evident—general pessimism about the
effect on individual doctors and concern about
political interference nationally and locally. The
opinion leaders saw potential advantages in terms of
guaranteed quality of the medical workforce. The main
disadvantages were the costs of what was seen as a
highly bureaucratic process and the possible negative
impact on doctors themselves.
The stakeholders accepted that at some point a
recently revalidated doctor would be found in breach
but had different views on the likely consequences of
this. One opinion leader thought that sensitivity and
reliability tests would come, whereas another saw the
potential for a huge loss of credibility. Expectations had
been built up high, and each time there had been a
reiteration of the problems of poor practice, the
General Medical Council was said to have come out
and stated, “Don’t worry, revalidation’s coming.”
Nevertheless the opinion leaders thought that
professional self regulation would endure for the fore-
seeable future, though its importance might wane.
Equally though the profession and its regulator had to
deliver.
Where does revalidation sit now?
The historian AJP Taylor commented that the greatest
decisions are nearly always the ones most difficult to
explain simply.9 So it is with revalidation. For although
the main stakeholders agreed in principle on the
policy, they reached only partial consensus on the
reasons for revalidation, its purpose, its place among
other mechanisms, and its likely effects. Given this
background and the recent guidance which overtly
links revalidation with appraisal, what might be the
implications for the future?
Clearly the chief protagonists have seen value in
revalidation, but it has had its critics. Some have argued
that the purpose is not clear, and needs to be so that
doctors and patients know what to expect10; others that
Opinion leaders and policy makers interviewed
Interviews were in summer of 2001; T = telephone
interview and F = face to face interview
The profession
• Chairman of council, Royal College of General
Practitioners (T)
• Chairman, General Practitioners Committee of the
British Medical Association (F)
• Chairman, British Medical Association (F)
• Chairman, Academy of Medical Royal Colleges (T)
• President, Royal College of General Practitioners (T)
The government
• Chief medical officer (for England) (F)
• Chief executive, Commission for Health
Improvement (T)
• Chair, National Clinical Assessment Authority (T)
• Chief executive, NHS Confederation (T)
• Chair, National Institute for Clinical Excellence (F)
• Clinical director of primary care for the NHS (in
England) (T)
The regulator
• President, General Medical Council (F)
• Lay member, General Medical Council, and Chair,
Patients’ Representative Group (T)
• Lead for General Medical Council on piloting
revalidation (F)
Other stakeholders
• Chair, Patients Association (T)
• Deputy chief nursing officer (for England) (T)
• Director, College of Health (T)
• Editor, British Medical Journal (T)
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the process is not fit for purpose.11–13 In particular there
is confusion about whether revalidation is intended to
detect poor performance, and if so, whether the proc-
ess will suffice. Formative appraisal and summative
revalidation are seen as uneasy bedfellows.13 14
For most doctors the process will entail participa-
tion in an appraisal system, which must be aligned with
the headings in Good Medical Practice and quality
assured to the satisfaction of the General Medical
Council.15 The Council states that such participation
will be “a powerful indicator of a doctor’s current
fitness to practise,”1 but makes no claim that the proc-
ess will be sensitive (identify poor performance),
specific (identify educational needs), valid (reflect
actual clinical practice), or reliable (behave consistently
across cohorts of doctors).16 Where there is any doubt
doctors will be invited to submit more information and
may be subjected to the performance procedures.
Conclusion
It is difficult to escape the conclusion that the purpose
of revalidation is as a form of professional regulatory
enforcer to ensure the NHS implements appraisal in a
designated manner. This may be enough to encourage
doctors to develop and to seek help early in case of dif-
ficulty. Alternatively, doctors relying for their revalida-
tion on five appraisals might be tempted to set easily
achievable objectives in their personal development
plans, rather than risk failing to meet a challenge. The
problems with this dual purpose have long been
recognised.17 In Pringle’s view, the most likely outcome
is the worst of all worlds, where the developmental and
formative nature of appraisal is lost, and where revali-
dation fails to identify poor performers.13
Whether patients and the government will be satis-
fied remains to be seen, particularly if (and predictably
when) a recently revalidated doctor is found to have
been a poor performer. Ultimately it may be more sen-
sible to separate revalidation from appraisal. Doctors
themselves could choose the independent route to
revalidation,1 by submitting other evidence of minimal
fitness to practise—appropriate tools are being
developed. Or we could move wholesale to such a
model (as in Canada), where a screening tool provides
feedback on performance to all while identifying the
minority of doctors at risk of being poor performers.
These doctors are then investigated in more depth.18
Patients and others might be more convinced by this.12
Finally, the impact on doctors and patients should
not be underestimated. In just over a decade, the NHS
has moved from being an organisation based on high
trust relationships to one where explicit written down
standards, which are monitored, have become the norm
for individuals and institutions. Revalidation is part of
this increased bureaucratic control being applied to
professional self regulation. It may increase apparent
accountability, but may not foster a culture which
increases patients’ trust and doctors’ professionalism.19
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Corrections and clarifications
Decline in mortality, AIDS, and hospital admissions
in perinatally HIV-1 infected children in the
United Kingdom and Ireland
Mis-reading of the alignment in table 3 of this paper
(table 2 in the abridged version) by D M Gibb and
colleagues led us to print the hazard ratios for death
and AIDS/death incorrectly for “How the child was
identified” (BMJ 2003;327:1019-23). The hazard
ratios for “prospectively from birth” and “after birth”
should be inverted: the values for children identified
after birth are therefore 1, and for children identified
prospectively from birth 0.49 (95% confidence
interval 0.31 to 0.78) and 0.44 (0.30 to 0.64).
ABC of smoking cessation: Nicotine replacement therapy
The table showing the formulations and availability
of nicotine replacement products in this article by
Andrew Molyneux contained an error (21 February,
pp 454-6). Nicorette nasal spray is licensed as a
Pharmacy (P) medicine and is available over the
counter at pharmacies; it is not a prescription-only
product, as stated in the table.
Effects of low dose ramipril on cardiovascular and renal
outcomes in patients with type 2 diabetes and raised
excretion of urinary albumin: randomised, double blind,
placebo controlled trial (the DIABHYCAR study)
A wrong reference number persisted to publication
of the full version of this article by Michel Marre
and colleagues (28 February, pp 495-9). In the fifth
paragraph of the Discussion, in the sentence
starting “Conversely, only 30% of the diabetic
patients . . .” the reference for the HOPE and
MICRO-HOPE studies should be reference 9
(not 11, as stated). The references in the abridged
version are correct.
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